Fumigillol compounds and methods of making and using same

Patent metadata

Field	Value
Publication number	US-9573918-B2
Application number	US-201314399392-A
Country	US
Kind code	B2
Filing date	May 8, 2013
Priority date	May 9, 2012
Publication date	Feb 21, 2017
Grant date	Feb 21, 2017

Abstract

The disclosure provides fumagillol type compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of using, e.g. in the treatment of obesity are provided.

First claim

We claim:

1. A compound represented by

wherein
R 1 is H or C 1-3 alkyl; or pharmaceutically acceptable salts or stereoisomers thereof.

2. The compound of claim 1 , represented by:

3. A compound represented by:

wherein
R 2 is selected from the group consisting of hydroxyl and isopropyl (optionally substituted with a hydroxyl);
R 3 is selected from the group consisting of H, and hydroxyl; or pharmaceutically acceptable salts or stereoisomers thereof.

4. A compound represented by:

wherein
R 4 and R 5 , together with the nitrogen to which they are attached, form a 4 membered ring optionally substituted by one or two substituents independently selected from the group consisting of methyl and hydroxyl;
or pharmaceutically acceptable salts or stereoisomers thereof.

5. The compound of claim 4 , represented by:

wherein
R 6 is selected from the group consisting of H, hydroxyl and methyl; and
R 7 is selected from the group consisting of H, hydroxyl and methyl.

6. A compound represented by

wherein
n is 1 or 2; or pharmaceutically acceptable salts or stereoisomers thereof.

7. A compound selected from the group consisting of:

and pharmaceutically acceptable salts or stereoisomers thereof.

8. A compound selected from the group consisting of:

and pharmaceutically salts or stereoisomers thereof.

9. A method of treating and/or controlling obesity, comprising administering to a patient in need thereof an effective amount of the compound of claim 1 .

10. A method of inducing weight loss in a patient in need thereof, comprising administering to said patient an effective amount of the compound of claim 1 .

11. The method of claim 9 , wherein the patient is a human.

12. The method of claim 9 , wherein the patient has a body mass index greater than or equal to about 25 kg/m 2 before the administration.

13. The method claim 9 , wherein the compound is administered orally, intravenously, or subcutaneously.

14. The method of claim 9 , wherein the compound is administered orally.

15. A pharmaceutical composition comprising the compound of claim 1 , and a pharmaceutically acceptable carrier.

16. The composition of claim 15 , wherein the composition is formulated as a unit dose.

17. The method of claim 9 , wherein the administering comprises administering said compound in an amount insufficient to reduce angiogenesis in the patient.

Assignees

• Zafgen Inc

Inventors

• Zahler Robert
• Vath James E

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• C07D405/14

  containing three or more hetero rings · CPC title

• A61K31/336 Primary

  having three-membered rings, e.g. oxirane, fumagillin · CPC title

• C07D303/46

  by amide or nitrile radicals · CPC title